Celcuity (CELC)

• Market cap: $5.29B
• 1 day: 3.11%
• 5 days: 0.19%
• 1 month: 9.29%
• 3 months: 11.78%
• 6 months: 107.41%
• Year to date: 13.6%
• 1 year: 1,038.78%
• 5 years: 746.07%
• 10 years: 699.3%
• Sector: Healthcare
• Industry: Biotechnology

About: Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Employees: 87